Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (39): 7259-7262.doi: 10.3969/j.issn.1673-8225.2011.39.010

Previous Articles     Next Articles

Drug prevention aganist periprosthetic osteolysis 5 years after total hip arthroplasty: A controlled randomized evaluation

Zhen Xin-gang, Wang Shao-qing, Yu Qiang   

  1. Department of Orthopedics, Fifth Hospital of Harbin, Harbin  150040, Heilongjiang Province, China
  • Received:2011-01-14 Revised:2011-03-12 Online:2011-09-24 Published:2011-09-24
  • Contact: Wang Shao-qing, Chief physician, Department of Orthopedics, Fifth Hospital of Harbin, Harbin 150040, Heilongjiang Province, China
  • About author:Zhen Xin-gang★, Master, Attending physician, Department of Orthopedics, Fifth Hospital of Harbin, Harbin 150040, Heilongjiang Province, China zhenxingang@163.com

PDF

355

Abstract:

BACKGROUND: The ideal drugs therapy for osteolysis may not only relieve the pain, but also save medical costs.
OBJECTIVE: To investigate the 5-year effect of alendronate and alfacalcidol combination on preventing periprosthetic osteolysis after total hip arthroplasty.  
METHODS: Seventy-five patients undergoing cemented total hip replacement after femoral neck fracture were randomly divided into 3 groups: the treatment group was given alendronate and alfacalcidol oral combination therapy, the control group was treated with compound amino acid chelate joint capsule of oral calcium therapy, and the blank control group with normal diet. Periprosthetic bone mineral density and average Harris score were examined at the 1st, 3rd, 5th years after the operation, and imaging evaluation after 5 years.
RESULTS AND CONCLUSION: Three and five years after hip replacement, bone density in treatment group was significantly higher than that in the control group (P < 0.05); 5 years after surgery, bone dissolution rate of the treatment group was lower than that of the control group and the blank control group (P < 0.05). The results showed that the combination of alendronate and alfacalcidol played a positive role in preventing the occurrence of osteolysis after hip prosthesis replacement.

CLC Number: